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Recombinant production and biochemical analysis of actin mutants has been hampered by the fact that actin has an absolute 
requirement for the eukaryotic chaperone CCT to reach its native state. We therefore have developed a method to rapidly screen the 
folding capacity and functionality of actin variants, by combining in vitro expression of labelled actin with analysis on native gels, band 
shift assays or copolymerization tests. Additionally, we monitor, using immuno-fluorescence, incorporation of actin variants in 
cytoskeletal structures in transfected cells. We illustrate the method by two examples. In one we show that tagged versions of actin do 
not always behave native-like and in the other we study some of the molecular defects of three β-actin mutants that have been 





Actin is the major component of the microfilament system of 
eukaryotic organisms and plays a central role in cell motility 
processes. Therefore it interacts with itself and with a broad array 
of actin binding proteins (ABPs) that regulate its polymerization 
(reviewed in (1)). Additionally, actin requires the help of the 
molecular chaperones CCT and prefoldin to adopt a properly 
folded state (2-4). In vitro characterization of naturally occurring 
disease-causing actin mutants (e.g. the α-actin mutants causing 
nemaline myopathy, (5)) and studies of interactions of actin and 
its partner proteins often require the generation of mutant actins. 
However, recombinant production and purification of actin 
mutants for biochemical studies is a laborious process (e.g. 6-8) 
and not possible in bacteria, since the bacterial chaperonin 
analogue GroEL (9) is incapable of productively folding actin 
(10). Moreover, we have shown, that introducing mutations in β-
actin can result in an unfolded, not-functional molecule (11). 
Consequently, there is need for a method to rapidly check if an 
actin variant is functional, before going through the effort of 
expression and purification. The method we here present fulfils 
this need and additionally allows gaining some biochemical 
insight in the behaviour of actin variants. It originates from our 
work on monitoring the folding capacity and functionality of 
actin and artificial actin mutants and consists of analysing 35S-
labeled actins, produced in reticulocyte lysate, via native gel 
electrophoresis, bands shift assays and copolymerization tests in Rommelaere et al.    
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addition to transfection in cultured cells (11). The use of the 
method is illustrated by two examples: 1) we investigate the 
influence of adding tags to actin on its functionality, and 2) we 
characterise three disease associated β-actin mutants. 
 
The first example was chosen to check if tagged proteins behave 
native-like, which is an important issue, considering that the use 
of tagged proteins became very popular in recent years. Tags like 
GST or HIS are generally added to facilitate purification of 
proteins, and in this case systems have been developed to remove 
the tag. This avoids having the tag interfere with the function of 
the protein of interest (reviewed in (12)). On the other hand, tags 
like GFP, myc or FLAG are added with the aim of visualising 
transfected proteins inside cultured cells. For most tags, cells 
have to be fixed and stained with an antibody against the tag. 
GFP-tagging however offers the advantage that it can be 
observed in living cells (13). Since the tags are essential for the 
visualization of the protein under investigation, they cannot be 
removed and consequently it is possible tags may interfere with 
the protein’s cellular activity and we show here that this is indeed 
the case for human β-actin molecules tagged with GFP at the N-
terminus or with a myc-tag at the C-terminus. 
 
In the second example, we employ our assay on three clinical β-
actin isolates: R28L and G245D, both associated with 
tumorigenesis (14, 15) and E364K, discovered in a patient with 
neutrophil dysfunction (16). Actin R28L (also called beta m-
actin) was isolated from a low metastatic B16 melanoma mouse 
cell line. Its expression however disappears or is very low in 
highly metastatic B16-F10 cell lines (17). Introduction of the 
mutant in these cells even reduces invasiveness and metastatic 
ability (14, 18). G245D was isolated from a tumorigenic human 
fibroblast cell line (HuT-14) (19). When HuT-12 fibroblasts 
transfected with this mutant and expressing high levels of it, are 
introduced in athymic mice, subcutaneous tumours are generated 
and the expression of tropomyosins is elevated (20). E364K was 
expressed together with normal β-actin in a female patient 
suffering from recurrent infections, photosensitivity and mental 
retardation. She had also abnormalities in neutrophil chemotaxis 
(a process connected to actin), superoxide production and 
membrane potential response (16). Using our assays, we could 
not find any defect for R28L, but G245D shows decreased 
binding to the eukaryotic chaperonin CCT. E364K on the other 
hand, displays increased CCT and prefoldin binding and little 
protein is released in a correctly folded state. 
 
MATERIALS AND METHODS 
 
Construction of the β-actin mutants 
 
β-actin mutants were made with the Quik Change site directed 
mutagenesis kit (Stratagene) as described in Rommelaere et al. 
(11). N-terminal myc-tagged wild type and actin mutants were 
made by PCR starting from the appropriate actin cDNA in the 
pcDNA3.1 vector (Invitrogen) using a 5’ primer containing the 
myc-coding sequence, preceded by a HindIII site and followed 
by an KpnI/Nco I site and a 3’ primer containing a XbaI site. 
After restriction these fragments were ligated in HindIII-XbaI 
digested pcDNA3.1. 
 
N-terminal GFP-tagged actins were made from their myc-tagged 
versions by excision of the myc-tag coding sequence with Hind 
III and KpnI, and replacing it by the GFP cDNA equipped with 
a linker (coding for SGLRSVPT) which had previously been PCR 
amplified using a 5’ primer containing a HindIII site and a 3’ 
primer containing a KpnI site. C-terminally myc-tagged actins 
were made by cloning them in the pcDNA3.1/CMycA-vector 
using KpnI and XbaI. These constructs were sequenced at the 5' 
and /or 3' end of their coding sequence. 
 
Expression of actin mutants and band shift assays 
with actin binding proteins 
 
We expressed the actin mutants as 35S-labeled proteins in in vitro 
transcription translation reactions in reticulocyte lysate (Promega, 
for details see step-by-step protocols). After 1h30 of reaction, we 
determined the amount of 35S-actin in the various complexes by 
analysing the reaction products on non-denaturing gels, either with 
or without 200 µM ATP (21), and the total amount of expressed 
protein by analysis on denaturing denaturing SDS- (22) or tricine-
gels (23) followed by autoradiography and quantification by 
Phosphor imager analysis (Typhoon 9200 variable mode imager, 
Amersham Biosciences) and the ImageQuant software package. 
The analysis on denaturing gels is also important to check if the 
produced protein has the correct length. Actin is known to be 
proteolitically sensitive at its C-terminus (24), but only very minor 
degradation is observed for in vitro produced actin variants 
indicating that protease activity in reticulocyte lysates is low. 
 
For the band shift assays, 1 µl of the respective actin binding 
proteins was added to 3 µl of an in vitro transcription translation 
reaction. After 1 minute incubation, the mixture was analysed on 
native gels with 200 µM ATP. The final concentration of the 
respective actin binding proteins was 12.5 µM for thymosin β4, 
13 µM for profilin IIa, 2 µM for DNase I and 1 µM for VDBP. 
These concentrations are the minimal amounts of the actin 
binding proteins needed to cause a band shift of wild type actin, 
as was determined by a concentration series (data not shown). 
 
DNase I was purchased from Worthington and VDBP from 
Calbiochem. Thymosin β4 was chemically synthesized on a 
model 431A peptide synthesizer using solid phase Fmoc 
chemistry. Recombinant profilin-IIa was purified according to 
Lambrechts et al. (25). 
 
Time course experiments 
 
After 6 minutes of incubation of an in vitro 
transcription/translation reaction of actin or actin mutant 
G245D an excess of cold methionine (0.9 mM final 
concentration) was added. Aliquots of 5 µl were taken 6, 9, 12, 
15, 18, 21, 30, 45, 60 and 90 minutes after chasing, and put on ice 
to stop the reaction. 3 µl was analysed on a native gel with ATP 
to quantify the amount of CCT-bound and released actin and 1 Rommelaere et al.    
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µl on a denaturing tricine gel (23), to quantify the total amount 
produced actin. The relative amount of CCT-bound and released 




25 µl of an in vitro transcription translation reaction of wild type 
or mutant β-actin was centrifuged at 100,000 rpm in a Beckman 
airfuge to remove aggregates. To the supernatant, we added 25 µl 
of 12 µM α-actin in G-buffer (2 mM TrisHCl, pH 8, 0.2 mM 
CaCl2, 0.5 mM DTT, 0.2 mM ATP), to drive actin 
polymerization. This actin was purified from rabbit skeletal 
muscle according to Pardee et al. (26). This protocol includes gel 
filtration, whereby the cross-linked actin dimers, produced during 
the aceton extraction step (27), are removed. Note that α- and β-
actin isoforms are able to form copolymers (28).  
 
We adjusted the buffer conditions to 100 mM KCl and 1 mM 
MgCl2 (F-buffer) and allowed the actin to polymerise for 2 hours 
at room temperature. F-actin was pelleted by centrifugation at 
100,000 rpm for 20 minutes (= pellet 1). The supernatant (sn1) 
was removed, the pellet washed and resuspended in 80 µl G-
buffer. Actin was allowed to depolymerise overnight at 4°C. A 
second round of polymerization was induced for 2 hours. F-actin 
was pelleted by centrifugation at 100 000 rpm for 20 minutes (= 
pellet 2) and separated from the supernatant (sn2). Aggregates, 
sn1, sn2 and pellet 2 were analysed on a 12.5% SDS-gel followed 
by autoradiography. The amount of 35S-labeled actin in each 
fraction was quantified using phosphor imaging. All mutants 
were analysed at least three times. 
 
In vivo localization 
 
We transfected pcDNA3.1 vectors encoding GFP- or myc-
tagged β-actin (wild type or mutant) in NIH 3T3 fibroblast cells 
using electroporation or lipofectamin 2000 (BD Biosciences, 
Clontech). 24 hours after transfection, cells were washed with 
PBS and fixed with 3% paraformaldehyde, permeabilized with 
0.1% Triton X100 in PBS and incubated for 1 hour at room 
temperature with phalloïdin-alexa-red (Molecular Probes) and 
anti-myc-FITC antibody in the case of myc-tagged actin 
(Invitrogen). Stained cells were examined using a Zeiss Axioplan 
II epifluorescence microscope equipped with a X40 objective or 
an Olympus IX71 epifluorescence microscope equipped with a 
X100 objective. Images were taken using respectively a cooled 
CCD Axiocam Camera and KS100 software (Zeiss) or a cooled 
Spot Camera (Diagnostic Instruments) and Analysis software 
(Soft Imaging Systems). 
 
RESULTS AND DISCUSSION 
 
Native gel analysis and band shift assays for in vitro 
expressed actin  
 
The method we describe here consists of analysing 35S-labeled 
actins produced by in vitro transcription/translation in 
reticulocyte lysate, which endogenously contains the actin folding 
machines prefoldin and CCT (2, 4). As a follow-up we often 
transfect these variants in cultured cell lines. To combine these 
methods efficiently, it is necessary to clone the actin variants in a 
vector that possesses a T7 or SP6 promotor (for expression in 
reticulocyte lysate) and a promotor that allows expression in 
cultured cells. We found the pcDNA3.1 vector, containing a T7 
and a PCMV promotor, very suitable for this purpose. 
 
 
Fig. 1: Actin-complexes have different mobilities on different native gels. 
(A) Outline of the production and electrophoretic analysis of 35S-actin (variants) 
in reticulocyte lysate. Comparison of analysis on Safer (21), Hansen (34, 59) and 
MES-gels (2). The upper arrows indicate CCT-actin, the lower arrows released 
actin, * indicates CAP-actin, ** prefoldin-actin and H haemoglobin. (B) 
Autoradiogram of discontinuous 4.5% - 7.5% Safer gels showing band-shift 
assays for WT-actin and the actin mutant 360(A5). The latter is released from 
CCT but not folded, since it does not bind to any ABP tested. For WT-actin, 
thymosin β4 causes a small downward shift and profilin IIa a small upward shift. 
 
The in vitro expressed 35S-labeled actin variants are analysed in 
various ways: on denaturing or native gels, in a band shift assay 
or in a copolymerization test. Analysis on denaturing SDS- or Rommelaere et al.    
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tricine-gels followed by autoradiography is necessary to estimate 
the total amount of expressed protein and to check if the 
produced protein has the correct length. More accurate 
quantification can be obtained with phosphor imaging. Native gel 
analysis is performed in the presence or absence of ATP. It 
reveals the various actin complexes during its folding process, i.e. 
actin associated with CCT, actin associated with prefoldin and 
released actin (Fig. 1A). In some cases, the latter band is not 
observed, which means that the particular actin variant remains 
arrested on CCT and is not able to fold (11). In the absence of 
ATP an additional complex of actin-CAP can be observed. CAP 
is also endogenously present in reticulocyte lysates (29) and has a 
high affinity for the nucleotide free state of actin (11). Note that 
the actin band in gels without ATP has the tendency to smear. 
During electrophoresis some of the actin molecules loose their 
bound ATP (originating from the transcription/translation 
reaction) and since actin needs this nucleotide for its stability 
(30), this part of the population denatures. 
 
To check if the released actin is correctly folded, we perform 
band shift assays, previously developed by others (e.g. (21, 31)). 
In these assays we test if the actin variant is able to bind to a 
panel of ABPs that contact different surfaces of the actin 
molecule, in this case thymosin β4, profilin IIa, DNase I and 
VDBP (Fig. 1B). An upward or downward shift of the released 
actin species on native gels indicates binding. No binding to the 
majority of these proteins indicates that the released actin is 
incorrectly folded (see e.g. mutant 360(A5)* in Fig. 1B). If 
binding to only one of these proteins is abolished, it indicates 
that actin is changed in a region important for binding to this 
partner ((11), see also below). Also relatively weak interactions 
(i.e. thymosin β4 mutants: Kd 100 µM) can be monitored using 
this assay (32). We assume this is because during electrophoresis, 
high local concentrations of proteins are generated when moving 
towards the same pole (i.e. proteins with acidic pI’s to the anode) 
because of stacking. Indeed, a problem occurs when analysing 
proteins with a basic pI and high off rates. This is for example 
the case for one of the profilin isoforms. Profilin I and IIa have a 
similar Kd for actin (0.4 and 0.7 respectively, (25)). However, no 
complexes between profilin I (pI 8.46) and actin can be detected 
because this basic isoform migrates towards the cathode and out 
of the gel, whereas complexes with the more acidic isoform, 
profilin IIa (pI 6.55), can be observed. Cofilin, which has also a 
basic pI (8.22), but slightly lower than the one of profilin I, can 
migrate into native gels (33), which indicates that small 
differences in pI can have a great impact on the migration 
direction. Obviously this is linked to the pH at which 
electrophoresis is performed. This is in turn dependent on the 
temperature because the pKa-values of buffers (and especially of 
TRIS) change with temperature.  
 
As outlined above, native or non-denaturing polyacrylamide gels 
are used to analyse native proteins or protein-complexes. The 
migration of these proteins depends on their size, shape and 
charge and, as already mentioned, on the pH maintained during 
gel electrophoresis. Therefore a careful choice of the buffer 
system and of the acrylamide concentration of the gel is required, 
depending on the type of analysis. In our case for example, 4.5% 
Safer gels at pH 8.7 (21) are best suited to analyse and quantify 
actin folding and actin binding to CCT and CAP (Fig. 1A). To 
perform actin band shifts however, it is more adequate to use 
discontinuous 4.5% - 7.5% or 4.5% - 10% Safer gels (Fig. 1B). 
The upper 4.5% part of the gel prevents aggregation of the native 
actin when it enters the gel, whereas in the lower part, the higher 
acrylamide concentration compresses the protein bands, which 
facilitates judging the occurrence of a band shift. To analyse and 
quantify prefoldin-actin complexes however, 6%-13% 
discontinuous native gels at pH 7 according to Hansen et al. (34) 
are preferred, since they produce a sharp prefoldin-actin band 
(35) in contrast to Safer gels, where this band is rather diffuse. 
However Hansen gels are not suited to quantify actin-CCT 
complexes (Fig. 1A).  
 
Reticulocyte lysate contains large amounts of haemoglobin and 
this may disturb the electrophoresis. Therefore we never load 
more than 3 µl reticulocyte lysate/well on a mini-gel with ten 
lanes, and even then haemoglobin appears as a thick spot at 
approximately one third of the gel (see e.g. Fig. 1A) and in some 
cases this band is exactly at the position of the protein complex 
to analyse (e.g. actin-GroEL, (36)). In this case MES-gels with a 
pH of 6.7 exactly should be used. At this pH, haemoglobin does 
not enter the gel, whereas the actin-complexes do (Fig. 1A). 
 
All these examples illustrate that, depending on the protein and 
the application, electrophoresis conditions have to be carefully 
chosen and as much as possible standardized.  
 
*Note: Actin 360(A5) means that amino acids 360 to 364 of actin 
are changed to alanine (11). 
 
Tests for copolymerization capability of actin 
variants 
 
Another important feature of actin is its self-association 
capability, hence it is necessary to test if actin variants are still 
able to polymerise (the experimental outline is presented in Fig. 
2A). Since the combined amount of endogenous actin and 
produced actin (mutant) in reticulocyte lysates, is limited, we are 
obliged to add wild-type carrier actin to induce polymerization. 
With respect to the carrier actin, we use rabbit α-skeletal actin, 
since this actin is easy to purify, possesses all correct post-
translational modifications and forms mixed polymers with other 
actin isoforms (28). The use of this actin has however the 
drawback that one always has to include the WT non-muscle 
isoform as a control when analysing non-muscle actin variants 
and one can only estimate relative copolymerization capacities. 
But even when analysing α-skeletal muscle actin mutants it is very 
important to include in every test series a control with the wild 
type isoform. This is to account for differences in quality of the 
carrier actin and variability of different batches of reticulocyte 
lysates. The latter also results in variability of concentrations of 
the ABPs present in the lysate that may influence the critical 
monomer concentration and may sequester a population of the 
actin monomers. Comparison with the WT isoform however 
overcomes all these inconveniences.  Rommelaere et al.    
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Fig. 2: Outline and optimization of copolymerization tests. (A) Outline of 
the copolymerization assay for 35S-actin (variants) produced in reticulocyte lysate. 
The fractions that we analyse via SDS-PAGE are boxed. An extra spin of the 
depolymerized F-actin pellet 1 to remove residual polymer is optional (see 
comments in protocol) but was not performed in the present study. (B) Test to 
determine the optimal volume for depolymerisaton of actin in the 
copolymerization assay. Samples of in vitro transcription translation reactions and 
α-actin from rabbit skeletal muscle were mixed, induced to polymerise and 
pelleted. This pellet was solubilized in G-buffer in the indicated volumes and 
depolymerized overnight, and divided in two. One half was left unchanged (a), 
the other half was induced to polymerise by addition of salts (b). These two 
fractions were centrifuged and for both, supernatants and pellets were analysed 
on 12% SDS-gels. The upper panels show the autoradiograms, the lower panels 
the corresponding Coomassie stained gels. This test shows that the optimal 
volume for repolymerization at the actin concentration used in this assay is 80 µl 
(b) and that this volume is also sufficient for depolymerization (a). 
 
Prior to induction of polymerization, it is necessary to remove 
aggregates by high-speed centrifugation. This is particularly 
relevant when dealing with unstable actin mutants. After the first 
polymerization round, the F-actin polymers are pelleted by 
spinning at high speed and depolymerized, where after a second 
round of polymerization is initiated and F-actin pelleted again. 
Two rounds of polymerization are necessary to avoid unspecific 
binding of the actin variants to the filaments. Indeed there are 
ABPs present in the reticulocyte lysate that may associate with 
the filaments. By performing the second polymerization round 
these ABPs are diluted out (compare for instance the presence of 
additional protein bands on the Coomassie stained gels of sn2 
and pellet 2 in Fig. 6A). This is important if this particular ABP 
has two actin binding sites through, which an actin variant can 
indirectly associate with filaments.  
 
The amount of (mutant) actin in each fraction is then measured 
after SDS-PAGE by counting 35S either in the initial spin 
(aggregates) before addition of carrier actin and induction of 
polymerization, or in the supernatants (sn1 and sn2, containing 
G-actin) of the two high speed spins following polymerization, or 
in the final pellet (pellet 2, containing F-actin) as outlined in the 
protocol section and in Fig. 2A (see also below Fig. 3E and 6B). 
 
Fig. 3: Native gel analysis of differently tagged actins reveals a different 
behaviour. (A-D) Autoradiograms of native gels of 35S-labeled GFP- and myc-
tagged β-actin and mutants produced in in vitro transcription translation reactions. 
(A) WT β-actin in the absence (left) or presence (right) of ATP. (B) β-actin 
mutant 210(A5) in the presence of ATP. (C) Band-shift assay of N-terminally 
(left) or C-terminally (right) myc-tagged WT β-actin. Only the lower part of the 
gel is shown. (D) β-actin 350(A5) in the presence of ATP. The upper arrows 
indicate CCT-actin, the lower arrows released actin, * indicates CAP-actin, ** 
prefoldin-actin. (E) Copolymerization of β-actin compared to myc-β-actin (N-
myc) and β-actin-myc (C-myc). Samples of in vitro transcription translation 
reactions and α-actin from rabbit skeletal muscle were mixed, induced to 
polymerise and pelleted. The amount of 35S-labeled actin in aggregates, 
supernatants (sn1 and sn2) and pellet 2 (see Fig. 2A) were calculated after analysis 
on 12.5 % SDS-gels. One such a gel is shown below the graph, it also indicates 
that only minor cleavage at the C-terminus of actin occurs in lysate. 
 
We have tested various conditions to derive the most suitable 
parameters to perform the depolymerization and second 
polymerization step. Initially, we depolymerized actin pellet 1 by 
resuspending it in 500 µl G-buffer to assure complete 
depolymerization. To then re-establish the critical concentration 
for the second round of polymerization, one needs to 
concentrate the actin solution to +/- 50 µl using Microcon 10 
concentrators. However, the concentrator membranes bind 
significant amounts of actin. Therefore we tried to avoid Rommelaere et al.    
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concentration and searched for a balance between the minimal 
volume for depolymerization and the maximal volume for the 
second polymerization. Pellet 1 was solubilized in G-buffer in the 
volumes indicated in Fig. 2B and depolymerized overnight. One 
half of this reaction was left unchanged and the other induced for 
polymerization. After ultracentrifugation supernatants and pellets 
were analysed on 12% SDS-gels. The optimal volume for 
repolymerization is 80 µl at the carrier actin concentration used in 
this assay.  
 
We want to emphasise here that this assay only reveals the 
capacity of mutant actin to copolymerise with carrier actin. For 
detailed kinetic studies on the polymerization behaviour of 
mutants, or for clinically relevant copolymerization assays (e.g. 
50% disease related mutant with 50% WT-actin) recombinant 
expression and purification of the mutant actin is superior. For 
this purpose yeast can be used, although this recombinant actin is 
not completely post-translationally modified (e.g. not methylated 
at H73, 37) and a recent paper shows successful baculovirus 
expression of actin (38). However recombinant production in 
this manner is not trivial and cannot yet easily be done for a large 
panel of actin mutants. Therefore the method, described above, 
should also be viewed as a screening tool for choosing which 
mutants to express recombinantly and as a quality control, i.e. 
does the mutant fold properly? The latter is illustrated below 
where we investigate the influence of tags on the functionality of 
actin.  
 
Tags may interfere with the functionality of actin 
variants; also the location of the tag is of 
importance 
 
Since wild type actin gets incorporated in stress fibers after 
introduction in cultured cells (39), the effect of actin mutations is 
often tested in vivo by transfection of tagged actin mutants. 
Staining for the tag and co-staining with phalloidin allows 
monitoring if the actin variant is incorporated in the actin 
cytoskeleton or if it forms aberrant structures. It can indeed 
happen that a mutant with normal copolymerization capacity in 
vitro, behaves abnormally in the cellular context (e.g. α-actin 
mutant H40Y in (40)). Various tags either at the N- or C-
terminus of actin have been used to perform transfection and 
transformation experiments (e.g. 41-43). However many actin 
binding proteins interact at the bottom of subdomains 1 and 3 of 
actin (see Fig. 5A, (44)). Since the C- and N-terminus of actin are 
both located in subdomain 1, this is in the neighbourhood where 
tags will be located. Consequently, it is possible that these tags 
will interfere with binding of actin binding partners and perturb 
actin function when transfected in cells, alternatively tags may 
interfere with the folding machinery. For this reason we find it 
necessary to investigate the behaviour of tagged actin variants in 
the  in vitro system described above prior to transfecting actin 
variants in NIH fibroblasts. We compare the use of small and 
larger tags, also paying attention to their site of fusion. 
 
We first describe the effects of fusing the short myc-tag to 
respectively the N- and the C-terminus of actin. N- and C-
terminally myc-tagged actins behave completely like WT actin on 
native gels in the presence of ATP with respect to folding (Fig. 
3A). However, in the absence of ATP, no CAP-binding is 
observed for actin-myc. We have previously shown that actin 
mutant 210(A5) tightly binds to CAP, even in the presence of 
ATP (11). Despite this we observe no CAP-binding when this 
mutant has myc on the C-terminus (Fig. 3B). Similarly, when the 
binding capacity of actin-myc to thymosin β4, profilin IIa, DNase 
I and VDBP was tested, no shift was seen in the case of profilin 
IIa. These results indicate that the tag at this position interferes 
strongly with wild type actin function (Fig. 3C). Actin-myc also 
incorporates less in actin polymers in vitro (Fig. 3E) and when 
transfected in NIH3T3 fibroblasts, it accumulates in abnormal 
protrusions that stain with phalloidin, but it does not incorporate 
in actin stress fibers (Fig. 4A). Myc-actin however copolymerises 
quasi normally and incorporates nicely in stress fibers (Fig. 4A).  
 
 
Fig. 4: Expression of GFP-tagged actin and mutants in NIH 3T3 cells 
gives a different picture than expression of the myc-tagged versions. (A) β-
actin, 1. N-terminally myc-tagged, 2. C-terminally myc-tagged, 3 and 4. N-
terminally GFP-tagged. (B) β-actin 350(A5), 1. N-terminally myc-tagged, 2. and 3. 
N-terminally GFP-tagged. Left panels are phalloidin staining of filamentous actin, 
middle panels, anti-myc-FITC staining or GFP-fluorescence of the expressed 
variants, right panels overlay (phalloidin:  red; myc/GFP: green). Scale bar is 40 
micrometer. Rommelaere et al.    
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So we conclude that N-terminally myc-tagged actin behaves like 
non-tagged actin in our assays, whereas a C-terminal myc-tag 
interferes with in vitro and in vivo copolymerization, CAP and 
profilin IIa binding. Thus a tag on the N-terminus is preferable, 
as was also found for tagged ACT88F actin in Drosophila (43), 
although we cannot rule out that it will interfere with myosin 
binding, since myosin has been predicted to interact with the N-
terminus of actin (45). Interaction with filament binding proteins 
is however difficult to probe with our method, given the low 
concentrations of mutant actins produced in reticulocyte lysates.  
 
Since in some cases monitoring of living cells is required, we 
tested also the influence of a GFP-tag. We added this tag only at 
the N-terminus since even the smaller myc-tag interferes with 
functionality when fused to the C-terminus. Analysis on native 
gels reveals four discrete bands, of which only the lower one is 
representing folded actin, since it is the only band that shifts with 
our ABP cassette (Fig. 3A and data not shown). The identity of 
the other bands is presently unknown; one may represent 
prefoldin-actin and the two others not functional or incorrectly 
folded species. Indeed the fact that the CCT-binding of GFP-
actin is increased indicates this mutant has difficulties to fold 
properly and thus only a minor part of the GFP-actin reaches a 
functional form. Since this population also does not interact with 
CAP, it indicates that the GFP-moiety at the N-terminus also 
may interfere with other actin functions. When this GFP-actin is 
transfected in fibroblasts, we observe in half of the cells a partial 
incorporation in stress fibers (a significant amount of GFP-actin 
is not incorporated in stress fibers compared to myc-actin 
transfected cells), but in the others, aggregates are formed (Fig. 
4A). Probably in the latter case, the not correctly folded species 
are predominantly formed. The same phenomenon is observed 
with actin mutants. N-terminally myc-tagged actin 350(A5) for 
example, folds correctly (Fig. 3D) and incorporates in stress 
fibers in NIH3T3 cells, however the GFP-version of it, again is 
partly folded and in half of the cases does not integrate in stress 
fibers in transfected cells (Fig. 4B).  
 
In conclusion, our results show that a tagged actin does not 
necessarily behave similar to the non-tagged version. Therefore, 
we advise to monitor folding and functionality by native gel 
analysis of in vitro expressed labelled actins, as presented here. 
Obviously, this may also apply to other tagged proteins; for 
instance C-terminal tagged versions of profilin IIa have a 
dramatically reduced affinity for proline-rich sequences whereas 
their affinity for actin appears normal (46). In these cases other 
assays that are standard for the protein of interest can be used. 
This will give more credit to data based on transfection of tagged 
proteins in cultured cells, where tags may serve to visualise the 
target proteins or as bait for immuno-precipitations. In particular 
for the latter application a quality control may be necessary 
because this technique is presently being used for high-
throughput mapping of protein-protein interactions using e.g. 
mass spectrometry (47).  
Analysis of the disease associated β-actin mutants 
R28L, G245D and E364K reveals some of their 
molecular defects 
 
As a second illustration of our method, we characterized three 
disease associated β-actin point mutants. One is associated with 
neutrophil dysfunction (E364K) and two are connected to 
tumorigenesis (G245D and R28L). As can be seen on the 3D-
representation of actin (Fig. 5A, (48)), these mutations are 
dispersed in the 3D-structure, G245D is at the top of subdomain 
4, E364K at the right bottom of subdomain 1, while R28L is at 
the junction of subdomain 1 and 2. Native gel analysis shows that 
all three mutants are capable of folding, however the amount of 
folded protein in the case of E364K is severely reduced and the 
majority of the protein remains bound to CCT and prefoldin, or 
is aggregated (Fig. 5B). Also CAP binding is lost. This suggests 
this mutant is folding compromised or unstable. For R28L, the 
CAP binding is reduced. Since G245D is located in the middle 
binding region for CCT (36), and given that actin mutant 245(A5) 
is compromised in CCT-binding (Fig. 5C), and that the β-actin 
mutant G245A shows decreased CCT-binding (29), we 
investigated also the CCT-binding capacity of this mutant. 
Therefore we introduced this mutation in an actin variant, which 
lacks the first six amino acids and is folding compromised, as 
relative CCT-binding can only be reliably quantified when no 
folded protein is released (36). Indeed G245D shows decreased 
binding to the eukaryotic chaperonin CCT (Fig. 5C).  
 
The in vitro expression system also allows monitoring the kinetics 
of CCT-actin complex formation and folding, by performing 
time course pulse chase experiments. By adding cold methionine 
six minutes after initiation of the reaction, one can follow the fate 
of the molecules that are labelled in the first six minutes. In the 
case of G245D, it shows that this mutant accumulates in the 
initial phase less on CCT than wild type actin, but finally reaches 
a similar amount of folded actin, suggesting this mutant is 
synthesized more slowly than wild type actin (Fig. 5D). 
 
To test if the three mutants are correctly folded, we performed 
band shift assays with our ABP panel (Fig. 5E). The fact that all 
mutants shift with all tested proteins indicates they are correctly 
folded, however with our assay it is difficult to detect subtle 
differences in the affinity of the mutants for the ABPs (see also 
(11)). One would indeed expect a decreased affinity of E364K 
for profilin, since E364 is involved in a salt bridge with K125 of 
profilin I (49) and a decreased binding has been reported by 
Nunoi et al. (16), however the same mutation in the indirect flight 
muscle-specific Act88F actin of Drosophila melanogaster results in 
increased binding to profilin (7). Rommelaere et al.    
 
 
Biological Procedures Online • Vol. 6 No. 1 • October 25, 2004 • www.biologicalprocedures.com 
242
Fig. 5: The β-actin mutants R28L, G245D and E364K fold and bind to the 
tested ABPs, however G245D shows decreased binding to CCT and E364K 
is not efficiently released by CCT and prefoldin. (A) Ribbon representation of 
the actin fold (48) with the positions of the mutations R28L, G245D and E364K 
indicated in pink. ATP is in yellow. (B) Autoradiogram of a native gel analysis in 
the presence (right) or absence (left) of ATP of 35S-labeled β-actin and mutants 
R28L, G245D and E364K produced in an in vitro transcription translation 
reaction. Note that the lower mobility of E364K is due to the charge inversion. 
The upper arrow indicates CCT-actin, the lower arrow released actin, * indicates 
CAP-actin, ** prefoldin-actin. (C) Autoradiogram of a native and a denaturing gel 
analysis of β-actin(7-375), β-actin(7-375) G245D, and β-actin(7-375) 245(A5). The 
% CCT-bound actin (arrow) was calculated by dividing the amount of CCT bound 
target protein (quantified from the native gels), by the total amount of expressed 
protein, (quantified from the denaturing gels) relative to the 100% binding reference 
β-actin(7-375) (36). ** indicates prefoldin-actin. (D) Time course pulse chase of β-
actin G245D versus WT-actin. Aliquots of 3 µl of a time course pulse chase 
reaction for WT β-actin and β-actin G245D were stopped at the given time-
points and analysed on a native and a denaturing gel and quantified. The gels 
represented are for G245D. The upper arrow indicates CCT-actin, the lower 
folded actin. The relative amounts of CCT-bound and free actin were plotted in 
function of time. ▲represents Actin-CCT, * free actin, ♦G245D-CCT and ■ free 
G245D. (E) Autoradiogram of a native gel analysis in the presence of ATP of 35S-
labeled  β-actin mutants R28L, G245D and E364K produced in an in vitro 
transcription translation reaction (control), band shifted with either thymosin β4, 
profilin IIa, DNase I or VDBP. The upper arrow indicates CCT-actin, the lower 
arrow released actin, ** indicates prefoldin-actin. We do not know the identity of 
the band indicated with * in the lanes with DNase I, but it may represent a 
DNase I-actin-CAP complex. 
 
The next feature of the actin mutants we tested was their ability 
to copolymerise with purified β-actin (Fig. 6). R28L 
copolymerises normally and G245D shows a modest reduction in 
copolymerization capacity. This is not surprising since residue 
245 is part of a surface involved in the interaction between actin 
monomers (50). Studies of polymer formation with only actin 
mutant G245D, purified after expression in yeast, also show 
impaired polymerization although different conditions were used 
(6). E364K was mostly recovered in aggregates and in the 
supernatant (CCT and prefoldin bound actin remain in the 
supernatant), which is in agreement with the fact that only a 
minor fraction of the molecules is folded (see above). This 
probably results in the reduced amount of this mutant in the 
filamentous fraction. However Nunoi et al. (16), observed no 
defect in cell free polymerization of this mutant, but since they 
isolated this mutant from the cytosol fraction it is likely they 




Fig. 6: The β-actin mutants R28L, G245D and E364K are able to 
copolymerise, although E364K is more prone to aggregation. Samples of in 
vitro transcription translation reactions and α-actin from rabbit skeletal muscle 
were mixed, induced to polymerise and pelleted. The amount of 35S-labeled actin 
in aggregates, supernatants (sn1 and sn2) and pellet 2 (see Fig. 2A) were calculated 
(B) after analysis on 12.5 % SDS-gels (A). Upper panels are autoradiograms, 
lower panels the corresponding Coomassie stained gels, the arrow indicates the 
migration position of actin. 
 
We subsequently investigated whether the mutants could 
incorporate in actin structures when transfected as N-terminally 
myc-tagged proteins in NIH3T3 fibroblasts. This was indeed the 
case for R28L and G245D (Fig. 7A and B) and is in agreement 
with our in vitro results and with previous reports: R28L becomes 
part of the microfilaments (14, 17); G245D accumulates in stress 
fibers but does however not participate in the formation of the 
actin filament-rich perinuclear network (51) and the transfected 
fibroblasts show altered morphology. In the Drosophila Act88F Rommelaere et al.    
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actin, G245D is antimorphic with regard to flight and causes 
myofibrillar disruption even in the presence of two normal 
alleles. It is initially incorporated into myofibrils and later induces 
their degeneration from centre to periphery (52). 
 
 
Fig. 7: β-actin R28L and G245D are incorporated in stress fibers in 
NIH3T3 fibroblasts, whereas E364K resides in aggregates. Myc-β-actin 
R28L. (B) Myc-β-actin G245D. (C) Myc-β-actin E364K. Left panels are anti-myc-
FITC staining of the expressed mutants, middle panels phalloidin staining of 
filamentous actin, right panels overlay (phalloidin: red, myc: green). Scale bar is 40 
micrometer. 
 
In cells transfected with myc-E364K, the mutant actin is not 
incorporated into stress fibers, but forms aggregates in the 
cytoplasm (Fig. 7C). This is consistent with a folding defect and 
agrees with the observation that the E364K mutant induces in 
Drosophila the production of heat shock proteins (53). When it is 
homozygously expressed in a null strain, no myofibrils are 
formed, and it is antimorphic for flight ability when expressed in 
an Act88F null strain together with wild type actin. An amino 
acid substitution at the identical site in actin molecules of S. 
cerevisiae, E364A, provoked temperature sensitivity (54).  
 
In conclusion, so far we did not find a defect for the β-actin 
mutant R28L, but for G245D we found decreased CCT-binding 
and delayed synthesis, suggesting that fewer functional actin is 
formed in cells. How this can be related to tumour induction still 
remains a question. Both mutants are able to incorporate in the 
actin cytoskeleton. E364K on the contrary has an increased CCT 
and prefoldin binding, it is aggregation sensitive and only little 
protein is released in a correctly folded state. In cultured cells it is 
located in aggregates in the cytoplasm. The disease caused by this 





We have developed a method to rapidly screen the folding capacity 
and functionality of actin variants, by combining in vitro expression 
of labelled actins and their analysis via native gels, band shift assays 
and copolymerization tests. The method can in principle be 
extended to any other protein that migrates, alone or in complex 
with a particular partner, into native gels. We already showed the 
usefulness of this method for characterization of actin mutants (11, 
40) and such characterizations are becoming more and more 
important since the list of clinical actin mutants that are discovered 
is growing. In addition to the three disease-related β-actin mutant 
analysed here, more than sixty α-skeletal muscle actin mutants that 
cause nemaline myopathy have been isolated (5), four α-cardiac 
actin mutants that cause cardiomyopathy (55, 56) and recently five 
γ-actin mutants that are associated with dominant progressive 
deafness (DFNA20/26) (57, 58). Additionally, using this method, 
we show that tagged and non-tagged actins do not necessarily 
behave similarly. Especially the use of tags on the C-terminus of 
a c t i n  a s  w e l l  a s  G F P - t a g s  h a s  t o  b e  a v o i d e d .  T h e r e f o r e ,  w e  
recommend using the analytical method presented here to first 
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Protocol 1: In vitro transcription/translation 
 
Reticulocyte lysate (Promega)  12.5 µl 
TNT-buffer  1 µl 
T7 polymerase  0.5 µl 
Amino acids minus methionine  0.5 µl 
35S-methionine (10 mCi/ml ICN)  2.8 µl 
RNAguard RNase inhibitor (Amersham Biosciences)  0.5µl 
RNA-Cap structure analogue (m7G(5’)ppp(5’)G, New England Biolabs)  0.5 µl 
ATP (50 mM)  0.5 µl 
MgCl2 (10 mM)  1.25 µl 
H2O/buffer*   4.4 µl 
DNA (+/- 200 ng/µl)  2 µl 
Total volume  26.45 µL 
 
All reagents should be RNase free and sterile. 
 
Add all reagents and let react for 1h30 at 30°C. Analyse or store at –80°C till further use. 
 
*H2O is recommended by the manufacturer. We found that a mixture of water and buffer containing 50 mM KCl, 5 mM MgCl2, 1mM 
EGTA, 20 mM MES pH6.8 and 1 mM DTT in a 2/3 ratio results in higher expression levels than adding water alone. 
 
Protocol 2: Native and denaturing gels 
 
A) Native gels 
 
The dimensions of the gels we make are 9 × 8 cm × 0.5 mm (0.75 mm in the case of Hansen gels) and we use slots that can contain 15 
to 20 µl. It is very important that the gels are prerun and run at 4°C, higher temperatures cause in most cases aggregation. 
 
1. Safer gels (21) 
 
Gel composition for two gels: 
 
  4.5 %  7.5 %  10 % 
1M TRIS  250 µl  250 µl  250 µl 
1M glycine  1.94 ml  1.94 ml  1.94 ml 
30% acrylamide  1.5 ml  2.5 ml  3.3 ml 
2% bis-acrylamide  0.6 ml  1.0 ml  1.3 ml 
H2O  5.5 ml  4.1 ml  3.0 ml 
100mM ATP (optional)  20 µl  20 µl  20 µl 
10 % APS  100 µl  100 µl  100 µl 
TEMED  10 µl  10 µl  10 µl Rommelaere et al.    
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Running buffer:    
25 mM Tris (3.025 g/l), 194 mM glycine (14.55 g/l), 0.2 mM ATP (2 ml 100 mM, if required). 
The final pH at 4°C will be 8.7 (adjusting the pH is not necessary). Store at 4°C. 
 
5X loading buffer:  
50% running buffer, 50% glycerol, spatula point bromophenol blue. In the case of reticulocyte lysate this buffer is not added. 
 
Running conditions:  
prerun: 1h at 4°C and 175 V (to bring the gel at pH 8.7). 
run : +/- 1h at 4°C and 175 V (till the haemoglobin has reached one third of the gel or till the bromophenol blue has run off). Time 
may vary depending on the pI of the proteins to analyse. 
 




4.5 %  3 gels 
30% acrylamide; 0.8% bis-acrylamide  2.25 ml 
1M MES (pH 6.7)  1.2 ml 
500 mM EGTA (pH 7.5)  30 µl 
1 M MgCl2  15 µl 
H2O  11.25 ml
100 mM ATP (optional)  160 µl 
100 mM GTP (optional)  160 µl 
10% APS   100 µl 
TEMED  20 µl 
 
Running buffer: 80 mM MES/KOH pH 6.7 (80 ml 1 M), 1 mM MgCl2 (1 ml 1 M), 1 mM EGTA (2 ml 500 mM), 0.1 mM ATP (1 ml 100 
mM, if required) for 1 liter. Store at 4°C. It is important to use tanks that can contain sufficient amounts of buffer (e.g. approximately 
300 ml and 200 ml in the upper and lower tank, respectively) to avoid warming up of the system, and to avoid pH-changes. Sometimes 
it’s necessary to renew the buffers during the run. 
 
2X Loading buffer: 50% running buffer, 50% glycerol, spatula point bromophenol blue. 
 
Running conditions: 
prerun: 1h at 4°C and 100V. 
run: 100 V at 4°C until 15 min after bromophenol blue ran off the gel. 
 
3. Discontinue gradient native gels according to Hansen et al. (34, 59) 
 
Gel composition for four gels: 
 
  13 % separation  6 % stacking 
H2O  6.6 ml  11.4 ml 
48 % acrylamide; 1.5 % bis-acrylamide  4.7 ml  2.5 ml 
1.5 M 6-aminocaproic acid; 150 mM BisTris, pH 7 6 ml  7 ml 
Glycerol  3.6 ml    
10% APS   60 µl  90 µl 
TEMED  6 µl  9 µl Rommelaere et al.    
 
 
Biological Procedures Online • Vol. 6 No. 1 • October 25, 2004 • www.biologicalprocedures.com 
248
Running buffers: 
Anode buffer (+, lower chamber): 50 mM BisTris, pH 7 (10.4 g/l) 
Cathode buffer (-, upper chamber): 50 mM Tricine (8.95 g/l), 15 mM BisTris (3.135 g/l), pH 7  
 
2X loading buffer: 100 mM BisTris pH 7, 10 % glycerol, 4 mM glutathione, 2 mM methionine, 2 mM cysteine and spatula point 
Ponceau S. 
 
Running conditions: 20 min at 50 V (± 5 mA) at 4°C, remaining time at 13 mA (± 150 V) till red front reaches the bottom of the gel. 
 
B) Denaturing Gels 
 
Gel composition for 3 gels: 
 
  10% separation  4% stacking 
48 % Acrylamide; 
1.5 % bis-acrylamide  3.05 ml  1.0 ml 
3M Tris; 0.3 % SDS; pH 8.45  5.0 ml  3.1 ml 
87 % glycerol  1.87 ml  -- 
H2O  5.0 ml  8.24 ml 
APS  75 µl  95 µl 
TEMED  7.5 µl  25 µl 
 
Running buffer: 
Anode buffer (+, lower chamber): 0.2 M Tris pH 8.3 (24.3 g/l). 
Cathode buffer (-, upper chamber): 0.1 M Tris pH 8.25 (12.11g/l), 0.1 M Tricine (17.92 g/l),  
0.1 % SDS (5 ml 20%) (no pH adjustment necessary). 
 
5X loading buffer (1 ml): 200 µl 20% SDS, 24% glycerol, 50 µl 1M Tris-HCl pH 6.8, 20 µl β-mercapto-ethanol, 490 µl H2O, spatula 
point bromophenol blue. 
 
C) Treatment of gels after running 
 
Disassemble everything and stain the gel with Coomassie blue for 5 min. Handle the 4.5% gels with a lot of care, they break very easily, it is 
best to put the plate with the gel in the staining chamber and peel the gel carefully of. Destain for 15 min. Incubate the gel for 15 min in 
Amplify solution (Amersham). Put the gel on Saran wrap, and cover it with a piece of Whattman paper (1 mm). This assembly is then dried 
at 80°C in a gel dryer for 30 min. After drying the Saran wrap is peeled of and the gel can be fluorographed.  
 
Protocol 3: Copolymerization assay (Fig. 2A) 
 
1.  Perform an in vitro transcription translation reaction of wild type or mutant β-actin in a total volume of 26.45 µl (see protocol 1). 
After reaction, remove 1 µl and add it to 3 µl 2X Laemmli buffer for analysis to check for expression of the protein. 
2.  Centrifuge the remaining 25 µl at 100 000 rpm in a Beckman airfuge to pellet aggregates  
3.  Transfer the supernatant to a second airfuge tube. Add 50 µl 1X Laemmli buffer to the tube with aggregates for analysis. 
4.  To the supernatant, add 25 µl of 12 µM α-actin (purified from rabbit skeletal muscle according to Pardee et al., (26)) in G-buffer (2 
mM TrisHCl, pH 8, 0.2 mM CaCl2, 0.5 mM DTT, 0.2 mM ATP) and mix by pipetting up and down. 
5.  Add 1.6 µl 3M KCl and 0.5 µl 100 mM MgCl2  (= F-buffer conditions). 
6.  Allow to polymerise for 2 hours at room temperature 
7.  Pellet the actin filaments by centrifugation at 100 000 rpm for 20 minutes (= pellet 1).  
8.  Remove the supernatant (= sn1, 50 µl) that contains the unpolymerized actin and add 3 µl 5X Laemmli buffer for analysis. 
9.  Gently wash pellet 1 with G-buffer. Rommelaere et al.    
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10.  Resuspend pellet 1 in 80 µl G-buffer by pipetting carefully up and down.  
11.  Allow depolymerising overnight at 4°C. Although not performed here, residual filaments can be removed by centrifugation at 100 
000 rpm for 20 minutes before induction of the second round of polymerization 
12.  Induce a second round of polymerization by adding 1.6 µl 3M KCl and 0.5 µl 100 mM MgCl2, let polymerise for 2 hours at room 
temperature. 
13.  Pellet actin filaments by airfuge centrifugation at 100 000 rpm for 20 minutes (= pellet 2). 
14.  Remove the supernatant (=sn2, 80 µl) and add 3 µl 5X Leammli buffer for analysis. 
15.  Pellet 2 is dissolved in 50 µl Laemmli buffer. 
16.  Analyse 2 µl of the aggregates, 2 µl of sn1, 10 µl of sn2 and 10 µl of pellet 2 on 12.5% SDS-gels (see Fig. 6). The Coomassie stain 
of the gel shows in which fraction the carrier actin is retained (mostly in pellet 2, in case of capping activity, in the supernatants). 
17.  Quantify the amount of 35S-labeled actin in each fraction using phosphor imaging and the ImageQuant software package. 
18.  To determine the total amount of 35S-labeled actin, multiply the amount for the aggregates by 5, for sn1 by 26.5, for sn2 by 8.3 and 
for pellet 2 by 5, and sum all these values.  
19.  The % of actin in each fraction is the total amount in each fraction divided by the total amount. 
 